COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Protocol No
DRAGONFLY-DF6002-001
Principal Investigator
Ariel Nelson
Phase
I/II
Summary
This part of the study will involve two groups of patients: group 2A and group 2B of this study will involve patients with one of 2 different types of locally advanced or metastatic solid tumors. Group 2A will involve patients with advanced melanoma; Group 2B will involve patients with advanced non-small cell lung cancer (NSCLC). Phase 2 groups 2A and 2B are part of the efficacy expansion in monotherapy.
Description
The purpose of this study is to test the levels of the investigational medicine (not approved by the FDA), named DF6002, in your blood, the safety of DF6002, and how people with some types of solid tumor cancers respond to the investigational medicine.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL